search

Active clinical trials for "Atrophy"

Results 191-200 of 856

Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal...

Atrophic Gastritis

It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects of age, sex, and Helicobacter pylori status on pepsinogen (PG) level for atrophic gastritis and whether gastric atrophy based on the PG test would be improved after H. pylori eradication.

Recruiting10 enrollment criteria

Modifiable Variables in Parkinsonism (MVP)

Parkinson's DiseaseParkinsonism7 more

We are trying to identify factors associated with improved quality of life and fewer PD symptoms. We are attempting to identify practices, beliefs, and therapies used by individuals who report excellent quality of life, few PD symptoms, and reduced rates of progression. After agreeing to participate, we will ask participants to fill our questionnaires about their experience with PD, their health in general, along with their food intake every six months for five years.

Recruiting7 enrollment criteria

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

Acute Rejection (AR) of Transplanted KidneyChronic Allograft Nephropathy (CAN)2 more

Chronic Allograft Nephropathy (CAN)/Interstitial fibrosis and Tubular Atrophy (IFTA) is responsible for most kidney transplant failures. CAN/IFTA on a 3 month kidney biopsy strongly predicts graft survival long term. CAN/IFTA remains a vexing problem for clinicians because current monitoring tools, namely the serum creatinine concentration, are not sensitive to early changes in glomerular filtration rate (GFR) or to histologic damage. Despite advances in prevention of acute rejection (AR), it is still a significant and potentially devastating complication of solid organ transplantation. One strategy to reduce the risk of rejection is to perform kidney biopsies to detect subclinical acute rejection (SCAR) and treat to prevent progression to rejection. There is evidence that treating SCAR can prevent further immune mediated injury to the kidney, a precursor to CAN/IFTA. Kidney biopsies provide better information but are limited due to safety concerns, patient preference and cost issues. Better, early and less invasive markers of CAN/IFTA will allow early intervention as well as improved graft and better patient outcomes. This study seeks to validate specific proteogenomic biomarker panels for AR and CAN/IFTA in a prospective blood, urine and kidney tissue monitoring study of kidney transplant recipients who will be scheduled for standard of care biopsies.

Recruiting8 enrollment criteria

C-Protein in Fatigue and Aging

AgingMuscle Atrophy or Weakness2 more

This study is investigating changes to the proteins in skeletal muscle that contribute to reduced muscle size and muscle function that occurs with aging.

Recruiting18 enrollment criteria

Carboxytherapy in the Treatment of Atrophic Scars

Atrophic Scar

To evaluate the efficacy of CO2 versus fractional CO2 laser versus platelet rich plasma in treatment of atrophic scars using clinical assessment and ultrasonography

Not yet recruiting2 enrollment criteria

Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study

Dry Age-related Macular DegenerationGeographic Atrophy5 more

An observational study to evaluate different biomarkers of subjects with geographic atrophy secondary to age-related macular degeneration

Recruiting7 enrollment criteria

Risdiplam in Patients With Spinal Muscular Atrophy Previously Treated With Nusinersen

Spinal Muscular Atrophy

Risdiplam Exchange (RISE) is a study of spinal muscular atrophy (SMA) patients who crossover to 36 months of open-label risdiplam monotherapy following a comparable period of nusinersen treatment. The schedule of assessments (SOAs) carry over seamlessly for the cohort from studies done while treated with nusinersen and continue to track the most informative outcomes from that trial (e.g. nine hole peg test and grip strength), while adding the Box and Block Test (BBT) as an additional measure of upper limb endurance and function.

Not yet recruiting6 enrollment criteria

Genital Laser Treatment in Postmenopausal Patients

DyspareuniaMenopause2 more

Regulation of sexual functions without hormonal support in order to correct the sexual dysfunctions in women with the estrogen hormone lost in the menopausal process. Recently, the reaction to hormonal treatments and the fact that patients with a family history of breast cancer or gynecological cancer cannot receive hormonal treatment have been the reason for applying to alternative treatments. Lubricant treatments are among the treatments that patients have compliance problems in the long term and avoid due to the difficulty of application. Correcting female sexual dysfunctions and post-menopausal women's right to want to feel sexually healthy are the most natural rights. Because sexual dysfunctions cause physiological and psychological problems in women. Thanks to the laser treatment, it is aimed to eliminate the atrophy and sexual dysfunctions of women, thanks to the application of approximately 2 sessions without the need for long-term medication.

Not yet recruiting8 enrollment criteria

Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants...

Spinal Muscular Atrophy (SMA)

The primary objective of the study is to evaluate anxiety level during intrathecal administration (IT) under standard of care (SOC) and virtual reality (VR) conditions using a reliable self-rating scale.

Recruiting12 enrollment criteria

Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases

Spinal Muscular AtrophyCharcot-Marie-Tooth Disease6 more

The goal of this study is to establish a genetic registry of patients with early-onset motor neuron and neuromuscular diseases. The investigators will collect samples from patients with a motor neuron or a neuromuscular disorder and their family members. The samples to be collected will be obtained using minimally invasive (whole blood) means. The research team will then extract high quality genomic DNA or RNA from these samples and use it to identify and confirm novel gene mutations and to identify genes which regulate the severity of motor neuron/neuromuscular diseases.

Recruiting3 enrollment criteria
1...192021...86

Need Help? Contact our team!


We'll reach out to this number within 24 hrs